Azacitidine and LDE255
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Azacitidine and LDE255
Azacitidine and LDE255 is a phase 1 stage product being developed by Novartis for MDS. The current trial status is completed. This product is registered under clinical trial identifier NCT02323139. Target conditions include MDS.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02323139 | Phase 1 | Completed |
Competing Products
20 competing products in MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 28 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 25 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| KRN321 | Kyowa Kirin | Phase 2 | 52 |
| Azacitidine + Venetoclax | AbbVie | Phase 1 | 33 |
| venetoclax + azacitidine | AbbVie | Phase 1 | 33 |
| Venetoclax + Azacitidine + Placebo | AbbVie | Phase 3 | 77 |
| venetoclax + azacitidine +/- donor lymphocyte infusion | AbbVie | Phase 1/2 | 41 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine) | Novartis | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| Azacitidine + Azacitidine plus Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox, Vitamin D and Azacitidine | Novartis | Phase 1/2 | 41 |
| LGH447 + LGH447 + midostaurin | Novartis | Phase 1 | 33 |
| Panobinostat | Novartis | Phase 1 | 33 |
| sabatolimab + azacitidine + venetoclax | Novartis | Phase 2 | 52 |
| LBH589 + Epoetin Alfa | Novartis | Phase 2 | 52 |
| Placebo + Romiplostim | Amgen | Phase 2 | 51 |
| Darbepoetin alfa + Placebo | Amgen | Phase 3 | 76 |
| Darbepoetin Alfa | Amgen | Phase 3 | 76 |